Volume 11, Number 3—March 2005
Research
Ebola Virus Antibody Prevalence in Dogs and Human Risk
Loïs Allela*, Olivier Bourry*, Régis Pouillot†, André Délicat*, Philippe Yaba*, Brice Kumulungui*, Pierre Rouquet*, Jean-Paul Gonzalez‡, and Eric M. Leroy*‡
Table 2
Prevalence rates of Ebola-specific immunoglobulin G antibodies in pet dogs from different areas and villages
| Area/village characteristic | No. | No. positive | Seroprevalence* (%) | 95% confidence interval (%) |
|---|---|---|---|---|
| France | 102 | 2 | 2 | 0.2–6.9 |
| Major towns (Libreville and Port Gentil) | 79 | 7 | 8.9 | 3.6–17.4 |
| Mekambo | 99 | 15 | 15.2 | 8.7–23.8 |
| Ebola virus–epidemic area (villages) | 159 | 40 | 25.2 | 18.6–32.6 |
| Villages with human cases | 92 | 25 | 27.2 | 18.4–37.4 |
| Villages without human cases | 67 | 15 | 22.4 | 13.1–34.2 |
| Villages with human cases and animal source | 66 | 21 | 31.8 | 20.9–44.4 |
| Villages with human cases, without animal source |
26 |
4 |
15.4 |
4.4–34.9 |
| *Seroprevalence rates were compared by using the Fisher exact test with a 0.05 confidence level. | ||||
¹Loïs Allela and Olivier Bourry contributed equally to this work.
Page created: April 25, 2012
Page updated: April 25, 2012
Page reviewed: April 25, 2012
The conclusions, findings, and opinions expressed by authors contributing to this journal do not necessarily reflect the official position of the U.S. Department of Health and Human Services, the Public Health Service, the Centers for Disease Control and Prevention, or the authors' affiliated institutions. Use of trade names is for identification only and does not imply endorsement by any of the groups named above.